NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Roche (peginterferon alfa 2-a,	Board of Community Health Councils in
ribavirin)	Wales
Merck Sharp and Dohme	British National Formulary
(peginterferon alfa 2-b, ribavirin)	Care Quality Commission
	Commissioning Support Appraisals
Patient/carer groups	Service
Action for Children	Department of Health, Social Services
Action for Sick Children	and Public Safety for Northern Ireland
Action on Hepatitis C	Healthcare Improvement Scotland
Addiction Today	Medicines and Healthcare products
Afiya Trust	Regulatory Agency
African HIV Policy Network	National Association of Primary Care
Association for Children with Life	NHS Alliance
Threatening or Terminal Conditions	NHS Commercial Medicines Unit
• AVERT	NHS Confederation
Black Health Agency	Public Health Wales NHS Trust
British Liver Trust	Scottish Medicines Consortium
Children's Liver Disease Foundation	
Children's Society	Possible Comparator manufacturer(s)
Co-infection Alliance	• N/A
Compass UK	
Drugs Action	Relevant research groups
Drugscope	Action on Addiction
Equalities National Council	Foundation for Liver Research
GMFA - The Gay Men's Health	MRC Clinical Trials Unit
Charity	National Institute of Health Research
Haemophilia Alliance	UCL Centre for Sexual Health & HIV Page 27th
Haemophilia Society	Research
Hepatitis A –Z	Assessment team
Hepatitis C Trust	Southampton Health Technology
Muslim Council of Britain	Assessment Centre
Muslim Health Network	, tooosinont contro
NAM Publications	Associated Guideline Groups
National AIDS Trust	- 1000 State Catalonia Croupe

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people

Consultees	Commentators (no right to submit or appeal)
 National Children's Bureau Positively UK South Asian Health Foundation 	National Collaborating Centre for Women's and Children's Health
 Specialised Healthcare Alliance Terrence Higgins Trust Transplant Support Network UK Harm Reduction Alliance WellChild Youth Net 	Associated Public Health Groups • TBC
Professional groups	
Association of Clinical Microbiologists	
Association of Medical MicrobiologistsAssociation of Nurses in Substance	
Association of Nurses in Substance Abuse	
British Association for Sexual Health	
and HIVBritish Association for the Study of the	
Liver	
British Association for the Study of the	
Liver Nurses Forum	
British Liver Nurses ForumBritish Society of Gastroenterology	
British Viral Hepatitis Group	
European Association for the	
Treatment of Addiction UK	
Haemophilia Nurses AssociationHCV Action	
Health Protection Agency	
Hepatitis Nurse Specialist Forum	
Infection Control Nurses Association	
 Medical Foundation for AIDS & Sexual Health 	
Royal College of General Practitioners	
Royal College of Nursing Royal College of Roadistries and Child	
 Royal College of Paediatrics and Child Health 	
Royal College of Pathologists	
Royal College of Physicians	
Royal Pharmaceutical Society	
Royal College of Physicians	

National Institute for Health and Clinical Excellence Provisional matrix for the appraisal of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people

Consultees	Commentators (no right to submit or appeal)
 UK Clinical Virology Network UK Haemophilia Centre Doctors' Organisation United Kingdom Clinical Pharmacy Association 	
Others	
Department of Health	
NHS Humber	
NHS Staffordshire	
Welsh Government	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

National Institute for Health and Clinical Excellence

Provisional matrix for the appraisal of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.